LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | Fedratinib | 0.37 | uM | LJP5 | 1 | L04 | 72 | hr | 1097 | 3574 | 3735 | 0.9568 | 0.9507 |
BT-20 | Fedratinib | 0.37 | uM | LJP5 | 2 | L04 | 72 | hr | 1097 | 3642 | 3877 | 0.9392 | 0.9323 |
BT-20 | Fedratinib | 0.37 | uM | LJP5 | 3 | L04 | 72 | hr | 1097 | 3401 | 3925 | 0.8664 | 0.8500 |
BT-20 | Fedratinib | 1.11 | uM | LJP5 | 1 | L03 | 72 | hr | 1097 | 3101 | 3735 | 0.8302 | 0.8001 |
BT-20 | Fedratinib | 1.11 | uM | LJP5 | 2 | L03 | 72 | hr | 1097 | 3239 | 3877 | 0.8353 | 0.8118 |
BT-20 | Fedratinib | 1.11 | uM | LJP5 | 3 | L03 | 72 | hr | 1097 | 3098 | 3925 | 0.7892 | 0.7584 |
BT-20 | Fedratinib | 3.33 | uM | LJP5 | 1 | L02 | 72 | hr | 1097 | 2573 | 3735 | 0.6889 | 0.6197 |
BT-20 | Fedratinib | 3.33 | uM | LJP5 | 2 | L02 | 72 | hr | 1097 | 2662 | 3877 | 0.6865 | 0.6268 |
BT-20 | Fedratinib | 3.33 | uM | LJP5 | 3 | L02 | 72 | hr | 1097 | 2558 | 3925 | 0.6517 | 0.5845 |
BT-20 | Fedratinib | 10 | uM | LJP5 | 1 | L01 | 72 | hr | 1097 | 752 | 3735 | 0.2013 | -0.1925 |
BT-20 | Fedratinib | 10 | uM | LJP5 | 2 | L01 | 72 | hr | 1097 | 815 | 3877 | 0.2102 | -0.1506 |
BT-20 | Fedratinib | 10 | uM | LJP5 | 3 | L01 | 72 | hr | 1097 | 702 | 3925 | 0.1788 | -0.2156 |
BT-20 | Trametinib | 0.04 | uM | LJP5 | 1 | P24 | 72 | hr | 1097 | 2687 | 3735 | 0.7194 | 0.6599 |
BT-20 | Trametinib | 0.04 | uM | LJP5 | 2 | P24 | 72 | hr | 1097 | 3198 | 3877 | 0.8247 | 0.7992 |
BT-20 | Trametinib | 0.04 | uM | LJP5 | 3 | P24 | 72 | hr | 1097 | 3250 | 3925 | 0.8279 | 0.8048 |
BT-20 | Trametinib | 0.12 | uM | LJP5 | 1 | P23 | 72 | hr | 1097 | 2963 | 3735 | 0.7933 | 0.7544 |
BT-20 | Trametinib | 0.12 | uM | LJP5 | 2 | P23 | 72 | hr | 1097 | 2973 | 3877 | 0.7667 | 0.7285 |
BT-20 | Trametinib | 0.12 | uM | LJP5 | 3 | P23 | 72 | hr | 1097 | 3187 | 3925 | 0.8119 | 0.7857 |
BT-20 | Trametinib | 0.37 | uM | LJP5 | 1 | P22 | 72 | hr | 1097 | 2913 | 3735 | 0.7799 | 0.7375 |
BT-20 | Trametinib | 0.37 | uM | LJP5 | 2 | P22 | 72 | hr | 1097 | 2936 | 3877 | 0.7571 | 0.7167 |
BT-20 | Trametinib | 0.37 | uM | LJP5 | 3 | P22 | 72 | hr | 1097 | 2735 | 3925 | 0.6967 | 0.6432 |
BT-20 | Trametinib | 1.11 | uM | LJP5 | 1 | P21 | 72 | hr | 1097 | 2510 | 3735 | 0.6720 | 0.5971 |
BT-20 | Trametinib | 1.11 | uM | LJP5 | 2 | P21 | 72 | hr | 1097 | 2936 | 3877 | 0.7571 | 0.7167 |
BT-20 | Trametinib | 1.11 | uM | LJP5 | 3 | P21 | 72 | hr | 1097 | 2833 | 3925 | 0.7217 | 0.6750 |
BT-20 | Trametinib | 3.33 | uM | LJP5 | 1 | P20 | 72 | hr | 1097 | 2750 | 3735 | 0.7362 | 0.6818 |